US and UK Reach Tariff-Free Deal on Prescription Drugs.
The UK and US have announced a major bilateral deal that will maintain no tariffs on UK drug shipments going into the American market.
The Terms of the Pact
As part of the deal, the UK has committed to increase expenditure on pharmaceuticals through the National Health Service (NHS). This move guarantees that tariffs on these crucial goods will remain at zero for a duration of three years.
This deal follows previous warnings to significantly raise import taxes on branded pharmaceutical products, with potential rates floated up to double the cost.
"This arrangement with the UK bolsters the international landscape for innovative medicines and introduces much-needed equity to U.S.–U.K. medicine commerce," an announcement said.
Economic Significance
Pharmaceuticals are one of the Britain's largest exports to the United States, which is clearly the largest destination for major UK drugmakers.
Statistics indicate that in the year prior to the third quarter, the UK exported pharmaceutical products worth £11.1bn to the US. This value accounted for a significant portion of total UK exports in that period.
"This deal secures work, stimulates capital expenditure and facilitates the UK to establish itself as a international leader for life sciences," a government official stated.
Detailed UK Commitments
The deal includes several notable pledges from the British government:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it deems new treatments to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to raise overall health service expenditure on drugs from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The amount manufacturers must refund to the NHS to stay within budget will be limited at 15%. In the past, refunds were more than 20%.
Recent Tensions
The pact comes amid a long-running row between the pharmaceutical industry and the UK government over medicine costs and approval rates.
The disagreement were intensified by claims that American patients were paying a premium for the identical medicines than patients in the Britain and the EU.
Recently, several significant pharmaceutical investments in the UK have been halted or cancelled, while major funding commitments have been announced toward projects in the United States.
A senior figure stated that the NHS had to invest a greater share on drugs, noting that its budget allocation on drugs had declined as a percentage of its total funding over the past decade.
